Surgical site infections (SSI) are one of the most common complications in the post-operative patient, and the second most common health care associated infection overall. It is estimated that there are between 500 thousand and 1.1 million surgical site infections in the United States each year. Given the magnitude of the problem, prevention of surgical site infections is a major goal of peri-operative care. However, skin preparation prior to surgery has not been as rigorously examined. The primary objective of this study is to compare the efficacy of two FDA approved, popular peri-operative skin preparations 2% chlorhexidine gluconate / 70% isopropyl alcohol to Iodine Povacrylex \[0.7% available Iodine\] / 74% Isopropyl Alcohol in the prevention of superficial surgical site infection. Male and female patients, age 18 years and older undergoing elective colorectal surgical procedures involving a laparotomy will be enrolled. These patients are at high risk of SSI. Eligible patients will be assessed at regular intervals for SSI and characterization of bacterial pathogen(s) in patients with SSI. Patients will remain enrolled into the study until 35 days postoperatively.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
802
Preoperative skin antisepsis preparation
preoperative skin antisepsis preparation
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
The Primary Objective Measures the Proportion of Patients With Superficial Site Infection as Defined by the CDC.
The primary objective compares the efficacy of 2% chlorhexidine gluconate / 70% isopropyl alcohol (ChloraPrep) to Iodine Povacrylex \[0.7% available Iodine\] / 74% Isopropyl Alcohol (DuraPrep) in the prevention of superficial surgical site infection. The primary objective will be measured by the number and percentage of patients with superficial site infection as defined by the CDC.
Time frame: within 35 days of randomization to treatment assignment
Time to Develop Surgical Site Infection
average time from surgery to surgical site infection diagnosis
Time frame: within 35 days of randomization to treatment assignment
Bacterial Pathogens Present in Documented Surgical Site Infection
Time frame: within 35 days of randomization to treatment assignment
Number and Percentage of Participants With Deep Wound Infection
Time frame: within 35 days of randomization to treatment assignment
Number and Percentage of Participants With Organ Space Infection
Time frame: within 35 days of randomization to treatment assignment
Length of Hospital Stay
Time frame: within 35 days of randomization to treatment assignment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.